Science Translational Medicine
Journal Information
ISSN / EISSN :
1946-6234 / 1946-6242
Current Publisher: American Association for the Advancement of Science (AAAS) (10.1126)
Former Publisher:
American Association for the Advancement of Science (AAAS) (10.1126)
Total articles ≅ 5,529
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
Filter:
Latest articles in this journal
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb8920
The publisher has not yet granted permission to display this abstract.
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abe2967
The publisher has not yet granted permission to display this abstract.
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb1498
The publisher has not yet granted permission to display this abstract.
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb0319
The publisher has not yet granted permission to display this abstract.
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.aaz6804
The publisher has not yet granted permission to display this abstract.
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abd9696
The publisher has not yet granted permission to display this abstract.
Published: 7 April 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abf1587
The publisher has not yet granted permission to display this abstract.
Published: 5 April 2021
Science Translational Medicine; doi:10.1126/scitranslmed.abf1906
Abstract:
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics which may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days, and clearance of 0.22 mL/hr/kg, consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study Day 6 following viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.
Published: 31 March 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.aba6322
The publisher has not yet granted permission to display this abstract.
Published: 31 March 2021
Science Translational Medicine, Volume 13; doi:10.1126/scitranslmed.abb0322
The publisher has not yet granted permission to display this abstract.